SHIELD THERAPEUTICS PLC (STX) — Q3 Trading Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SHIELD THERAPEUTICS PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Anders Lundstrom, CEO. Good afternoon, sir. Thank you, Lily. Hello, and welcome everybody to SHIELD THERAPEUTICS third quarter trading update presentation. So as you heard, my name is Anders Lundstrom. I'm the CEO. And together with me today is Santoshanbach, our CFO. Oh, and I have the slides. So here's our disclaimer. I understand you cannot read every word. This presentation will be posted on our website in the next couple of days. So not only so you can read the disclaimer, of course, so you can review any slides presented today as well. So, yes, as an as as in summary, so we at SHIELD THERAPEUTICS, we we're a fast growing mission driven specialty pharmaceutical company. We, commercialize on our own in The US and in the rest of the world, we have partners that commercialize our product. So the market we're in is iron deficiency or iron deficiency anemia. It's in The US alone, it's about fifteen million people or patients who, have this medical condition. The challenge for patients and and, treaters are that about up to sixty percent of patients that use traditional oral lines often gets different type of gastrointestinal side effects...